Tenaya Therapeutics, Inc. (TNYA)

Over the past six months, Tenaya Therapeutics completed a public offering, raising approximately $55.8 million, which extended the cash runway into the second half of 2027 but led to share dilution. The company reported positive interim clinical data for TN-401 and TN-201. Tenaya received a Nasdaq notice for failing to meet the minimum bid price requirement. The company entered into a research collaboration with Alnylam Pharmaceuticals. Preclinical data for TN-301 was presented at MDA 2026. The company reported its Q4 and full-year 2025 financial results. There has been insider selling activity. The broader biotechnology sector experienced a downturn.

As a clinical-stage biotechnology company without commercialized products, Tenaya Therapeutics does not have traditional demand seasonality. Its revenue streams are primarily derived from collaborations, grants, and equity financings rather than product sales.

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and delivering curative therapies for heart disease by targeting the underlying molecular causes. The company operates in the Healthcare sector and Biotechnology industry, advancing its pipeline through Gene Therapy, Cellular Regeneration, and Precision Medicine platforms. Key product candidates include TN-201 for MYBPC3-associated HCM, TN-401 for PKP2-associated ARVC, and TN-301 for heart failure and related cardio/muscular diseases. The company also has early-stage programs in preclinical development.

Tenaya Therapeutics is headquartered in South San Francisco, California, and operates a Genetic Medicines Manufacturing Center in Union City, California.

Tenaya Therapeutics' reputation has been shaped by progress in clinical trials, strategic collaborations, and financial activities. Positive developments include promising interim data for TN-201 and TN-401, and a research collaboration with Alnylam Pharmaceuticals. Negative impacts include a Nasdaq notice for failing to meet the minimum bid price requirement and share dilution from a public offering. The decommissioning of an internal manufacturing facility and shifting to outsourcing also represents a strategic shift that could be viewed in various ways by stakeholders.

Tenaya Therapeutics is owned by a mix of institutional shareholders, insiders, and retail investors. Institutional shareholders hold 31.61% of the stock, insiders hold 38.17%, and retail investors hold 30.22%. Major institutional owners include Column Group LLC, Vanguard Group Inc, and Empery Asset Management, LP. The largest individual shareholder is Column Group III GP LP, owning 59.18 million shares, representing 27.27% of the company.